Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer

Authors

  • Derrick T. Lin MD,

    1. Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Kotha Subbaramaiah PhD,

    1. Department of Medicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, 1300 York Avenue, Room F-206, New York, New York 10021
    Search for more papers by this author
  • Jatin P. Shah MD,

    1. Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Andrew J. Dannenberg MD,

    Corresponding author
    1. Department of Medicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, 1300 York Avenue, Room F-206, New York, New York 10021
    • Department of Medicine, Weill Medical College of Cornell University and Strang Cancer Prevention Center, 1300 York Avenue, Room F-206, New York, New York 10021
    Search for more papers by this author
  • Jay O. Boyle MD

    1. Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author

  • Carl H. Snyderman, MD, Section Editor

Abstract

Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including oral leukoplakia and squamous cell carcinoma of the head and neck. Increased levels of COX-2 may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. In experimental models, newly developed selective COX-2 inhibitors suppress the formation of tumors, including tongue cancer. These findings provided a rationale for a number of chemoprevention trials that are underway. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. In this review, evidence is presented that inhibition of COX-2 represents a promising strategy to prevent or possibly treat human head and neck cancers. © 2002 Wiley Periodicals, Inc. Head Neck 24: 792–799, 2002

Ancillary